Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Conditions: Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor Intervention: Drug: CLR 131 Sponsor: Cellectar Biosciences, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2018 Category: Research Source Type: clinical trials